1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Euronext Paris  -  11:35 2022-08-19 am EDT
1.279 EUR   -0.43%
08/04Novacyt Launches First Fully Lyophilized Direct-to-PCR Assays; Shares Up 5%
MT
08/04Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays
CI
07/28Novacyt Creates Research-use-only Adenovirus F41 Test Kit Amid Rising Hepatitis Cases
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

France's Novacyt Rolls Out Monkeypox Assay

06/28/2022 | 03:03am EDT


© MT Newswires 2022
All news about NOVACYT
08/04Novacyt Launches First Fully Lyophilized Direct-to-PCR Assays; Shares Up 5%
MT
08/04Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-P..
CI
07/28Novacyt Creates Research-use-only Adenovirus F41 Test Kit Amid Rising Hepatitis Cases
MT
07/28Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay
CI
07/21NOVACYT : Results of Annual General Meeting
PU
07/21NOVACYT : AGM Investor Presentation
PU
07/15Novacyt - Approval of exsig COVID-19 Direct test in the UK under CTDA legislation
AQ
07/15UK Watchdog OKs Novacyt's exsig COVID-19 Direct Test
MT
07/15Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK
CI
07/07NOVACYT : Half-year results
CO
More news
Financials
Sales 2021 95,8 M - -
Net income 2021 -9,73 M - -
Net cash 2021 99,9 M - -
P/E ratio 2021 -31,3x
Yield 2021 -
Capitalization 90,7 M 91,0 M -
EV / Sales 2020 2,17x
EV / Sales 2021 2,19x
Nbr of Employees 276
Free-Float 94,8%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
David Allmond Chief Executive Officer & Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Paul Oladimeji Group Head-Research & Development
Bryan Close Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-70.68%92
GILEAD SCIENCES, INC.-10.23%81 694
VERTEX PHARMACEUTICALS34.01%75 473
REGENERON PHARMACEUTICALS, INC.-1.06%66 800
MODERNA, INC.-40.94%58 680
LONZA GROUP AG-24.63%44 689